Status:
COMPLETED
Medication Use Evaluation (MUE) for Continuous Heparin Infusions in Hospitalized Patients
Lead Sponsor:
Methodist Health System
Conditions:
Unfractionated Heparin
Eligibility:
All Genders
18-75 years
Brief Summary
Unfractionated heparin (UFH) is an anticoagulant to prevent thrombus formation or worsening of an existing thrombus. It is indicated for patients with deep vein thrombosis/pulmonary embolism (DVT/PE) ...
Detailed Description
Unfractionated heparin is classified as a high-alert medication in the acute care setting.3 Therapeutic anticoagulation is a high priority for healthcare teams because the impacts of inadequate antico...
Eligibility Criteria
Inclusion
- Patient's aged 18 years or older with a confirmed diagnosis of DVT/PE based on imaging or a confirmed diagnosis of ACS requiring heparin therapy
Exclusion
- History of bleeding in the last 30 days
- History of HIT
- Use of systemic anticoagulants for another indication
- Presence of coagulation disorder prior to admission (i.e. hemophilia, sickle cell anemia, etc.)
Key Trial Info
Start Date :
October 31 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 21 2023
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06096064
Start Date
October 31 2022
End Date
August 21 2023
Last Update
October 23 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Methodist Richardson Medical Center
Dallas, Texas, United States, 75082